NEW YORK (GenomeWeb News) — Roche plans to buy an Alnylam research facility in Germany, has licensed Alnylam’s RNAi IP, and will work with the RNAi company on drug-discovery projects, Roche said today.

 

Under the agreement, worth $331 million plus unknown milestones and royalties, Roche will acquire the Alnylam lab in Kulmbach, along with about 40 employees, once the deal is cleared by regulators in around 30 days, Roche said. Roche will use the site to create a Center of Excellence for RNAi therapeutics research.